Company: MDCXW
Filing Date: 2025-09-19
Form Type: DRS
Source: 0001062993-25-015719
Chunk: 13

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-19
Form: DRS
Chunk 13
---
, 2025 with an exercise price of $2.80 per Common Share (the "Regulation A Warrants"), in consideration for receiving the 2,680,000 warrants to purchase common shares with an exercise price of $3.75 (the "Private Warrants"). In accordance with the Warrant Inducement Agreement, Armistice exercised its Regulation A Warrants for cash, for gross proceeds of $3,752,000 to the Company.

<div align='center'>4

CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD.

PURSUANT TO 17 C.F.R. SECTION 200.83</div>

Other Corporate Updates

On May 22, 2025, the Company announced that it has received study may proceed approval from the United Arab Emirates Department of Health to commence Phase 2 clinical study (SKNJCT-004) to non-invasively treat basal cell carcinoma ("BCC") of the skin.

On June 23, 2025, the Company announced the appointment of Andrew Smith, age 57, to serve as the Company's Chief Operating Officer ("COO"). Mr. Smith first joined the Company as a consultant on May 27, 2025 and transitioned to his new role as COO on June 30, 2025.

On July 29, 2025, the Company and Deloitte LLP ("Deloitte") entered into an engagement letter whereby Deloitte was appointed as the exclusive lead financial adviser to the Company for the purpose of finding one or more partners for an out-licensing transaction for D-MNA for the treatment of BCC in adults, whether by license, option, or other agreed structure or mechanism.

On August 4, 2025, the Company announced that it entered into a non-binding memorandum of understanding with Helix Nanotechnologies Inc. ("HelixNano"), a Boston-based biotech company focused on developing an advanced mRNA platform to create vaccines and therapies to augment the immune system's power to fight disease, with the aim of forming a joint venture for the co-development and commercialization of thermostable mRNA-based vaccines utilizing each company's respective proprietary technologies. In parallel with such ongoing negotiations, Medicus and HelixNano have formalized their mutual intent to collaborate on the research, development and production of a batch of clinical-grade mRNA vaccine-loaded MNAs, which are intended for use in a Phase 1 clinical bridging study to compare the safety and preliminary efficacy of intramus